Acceptance and Opinions of Intanza/IDflu Intradermal Influenza Vaccine in the Czech Republic and Turkey

Creative Commons License

Prymula R., USLUER G., Altinel S., Sichova R., Weber F.

ADVANCES IN THERAPY, vol.29, no.1, pp.41-52, 2012 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 29 Issue: 1
  • Publication Date: 2012
  • Doi Number: 10.1007/s12325-011-0090-5
  • Journal Name: ADVANCES IN THERAPY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.41-52
  • Eskisehir Osmangazi University Affiliated: Yes

Abstract

IntanzaA (R)/IDfluA (R) (Sanofi Pasteur SA, Lyon, France), a split-virion, trivalent influenza vaccine delivered by intradermal injection with a microinjection system, became available in adults 18-59 years of age (9 mu g) and a parts per thousand yen60 years of age (15 mu g) as of the 2010/2011 northern hemisphere influenza season.